Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?

Bristol Myers Squibb's (BMY) CAR T cell therapy, Breyanzi, reported strong Q2 sales, surging 125% to $344 million, with U.S. sales doubling to $255 million, driven by robust demand, new indications, and manufacturing improvements. This growth is critical as BMY leverages Breyanzi and its immuno-oncology portfolio to offset generic competition for legacy drugs, further bolstered by the FDA granting Priority Review for Breyanzi in marginal zone lymphoma with a December 5, 2025, target action date. Despite facing competition from Gilead's Yescarta and Novartis's Kymriah, Breyanzi's uptake is pivotal for BMY, whose shares are down 17.7% year-to-date and trade at a valuation discount.

Analysis

Bristol Myers Squibb's (BMY) CAR T therapy, Breyanzi, demonstrated significant commercial momentum in the second quarter, with sales surging 125% to $344 million, driven by strong demand and improved manufacturing success. This growth, particularly the doubling of U.S. sales to $255 million, is critical to the company's strategy of using its new immuno-oncology portfolio to counteract revenue erosion from legacy drugs facing generic competition. However, this product-level success is contrasted by substantial headwinds for the parent company. Breyanzi trails Gilead's competitor Yescarta, which posted higher Q2 sales of $393 million, indicating a highly competitive market. Furthermore, BMY's stock has severely underperformed, declining 17.7% year-to-date against the industry's 0.9% drop. This market pessimism is reflected in its discounted valuation, with a forward P/E ratio of 7.49x, and a recent downward revision of its 2025 bottom-line estimate, suggesting Breyanzi's strength is not yet sufficient to overcome broader challenges across the company.

Key Decisions for Investors

• Given the significant stock underperformance and downward revision of 2025 earnings estimates, investors should be cautious, as Breyanzi's impressive growth may not be enough to offset broader company headwinds and strong competition from Gilead's Yescarta.
• For value-oriented investors, BMY's discounted valuation at a 7.49x forward P/E, combined with Breyanzi's 125% sales growth, could present a long-term entry point, contingent on the new drug portfolio successfully stabilizing the company's revenue base.
• Monitor the FDA's decision on Breyanzi for marginal zone lymphoma, with a target date of December 5, 2025, as a potential near-term catalyst that could expand the drug's addressable market and influence future growth trajectory.